1. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

    JAMA 316(3):282 (2016) PMID 27434441

    The effectiveness of buprenorphine treatment of opioid dependence is limited by suboptimal medication adherence, abuse, and diversion. To determine whether 6-month buprenorphine implants are noninferior to daily sublingual buprenorphine as maintenance treatment for opioid-dependent patients with...
  2. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

    British journal of addiction 108(12):2141 (2013) PMID 23919595 PMCID PMC4669043

    To evaluate the safety and efficacy of buprenorphine implants (BI) versus placebo implants (PI) for the treatment of opioid dependence. A secondary aim compared BI to open-label sublingual buprenorphine/naloxone tablets (BNX). Randomized, double-blind, placebo-controlled trial. Subjects received...
  3. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

    JAMA 304(14):1576 (2010) PMID 20940383

    Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms. To determine the efficacy of buprenorphine implants that provide a low, steady level of buprenorphine over 6 months for the treatment of opi...
  4. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.

    Drug and Alcohol Dependence 103(1-2):37 (2009) PMID 19403243

    Buprenorphine, a mu-opioid receptor partial agonist, has been shown to be safe and effective for treatment of opioid dependence. A novel implantable formulation of buprenorphine (Probuphine), using a polymer matrix sustained-release technology, has been developed to offer treatment for opioid de...
  5. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia.

    The American Journal of Medicine 120(5):448 (2007) PMID 17466657

    We investigated the efficacy and tolerability of paroxetine controlled release, a selective serotonin reuptake inhibitor in fibromyalgia. After excluding patients with current major depression and anxiety disorders, 116 subjects with fibromyalgia were enrolled in a 12-week, randomized, double-bl...
  6. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

    Behavioural Brain Research 171(2):225 (2006) PMID 16782211

    Atypical antipsychotics, such as olanzapine, have been associated with clinically significant weight gain. Changes to the hypothalamic pituitary adrenal axis may partially mediate this weight increase. Two experiments were conducted to test the effects of mifepristone on both mitigating and prev...
  7. A randomized controlled trial of paroxetine for noncardiac chest pain.

    Psychopharmacology bulletin 39(1):15 (2006) PMID 17065971

    Noncardiac chest pain occurs frequently in medical practice and is often difficult to treat. We conducted a randomized double-blind, placebo-controlled, 8-week trial of paroxetine in 50 patients with noncardiac chest pain. None of the patients met criteria for panic disorder or major depression....
  8. Paroxetine treatment of depression with posttraumatic stress disorder: effects on autonomic reactivity and cortisol secretion.

    Journal of Clinical Psychopharmacology 24(2):131 (2004) PMID 15206659

    Effects of paroxetine treatment of comorbid depression and posttraumatic stress disorder (PTSD) on subjective symptoms, autonomic reactivity, and diurnal salivary cortisols were assessed prospectively. Cross-sectional baseline psychophysiologic assessments of 22 patients with depression + PTSD, ...
  9. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.

    JAMA 289(21):2827 (2003) PMID 12783913

    Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective. To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in tr...